These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31758441)

  • 1. Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient.
    Hemmersbach-Miller M; Alexander BD; Pieper CF; Schmader KE
    Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):455-463. PubMed ID: 31758441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients.
    Kamar N; Mengelle C; Esposito L; Guitard J; Mehrenberger M; Lavayssière L; Ribes D; Cointault O; Durand D; Izopet J; Rostaing L
    J Med Virol; 2008 Jun; 80(6):1012-7. PubMed ID: 18428146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study.
    Chitasombat MN; Watcharananan SP
    F1000Res; 2018; 7():1568. PubMed ID: 30473779
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience.
    McGuirk M; Shahzad M; Amin MK; Khan MA; Bellman P; Mudaranthakam DP; DeJarnette S; Lutfi F; Ahmed N; Bansal R; Abdelhakim H; Gorsline C; Shoemaker DM; Abdallah AO; Shune L; Abhyankar SH; Singh AK; McGuirk JP; Mushtaq MU
    Transpl Immunol; 2024 Jun; 84():102039. PubMed ID: 38513813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs.
    Schlott F; Steubl D; Hoffmann D; Matevossian E; Lutz J; Heemann U; Hösel V; Busch DH; Renders L; Neuenhahn M
    PLoS One; 2017; 12(1):e0171035. PubMed ID: 28129395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.
    Hughes D; Hafferty J; Fulton L; Friend P; Devaney A; Loke J; Welsh KI; Handa A; Klenerman P
    J Clin Virol; 2008 Feb; 41(2):92-5. PubMed ID: 18032098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.
    Beck JC; Wagner JE; DeFor TE; Brunstein CG; Schleiss MR; Young JA; Weisdorf DH; Cooley S; Miller JS; Verneris MR
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):215-22. PubMed ID: 19786112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses.
    Toupance O; Bouedjoro-Camus MC; Carquin J; Novella JL; Lavaud S; Wynckel A; Jolly D; Chanard J
    Transpl Int; 2000; 13(6):413-9. PubMed ID: 11140239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients.
    Maggi F; Focosi D; Statzu M; Bianco G; Costa C; Macera L; Spezia PG; Medici C; Albert E; Navarro D; Scagnolari C; Pistello M; Cavallo R; Antonelli G
    Sci Rep; 2018 Oct; 8(1):15490. PubMed ID: 30341363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?
    Bruminhent J; Thongprayoon C; Dierkhising RA; Kremers WK; Theel ES; Razonable RR
    Liver Transpl; 2015 Apr; 21(4):539-46. PubMed ID: 25597303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
    Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
    BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMV Viremia is associated with a decreased incidence of BKV reactivation after kidney and kidney-pancreas transplantation.
    Elfadawy N; Flechner SM; Liu X; Schold J; Srinivas TR; Poggio E; Fatica R; Avery R; Mossad SB
    Transplantation; 2013 Dec; 96(12):1097-103. PubMed ID: 24056621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab.
    Jain T; John J; Kotecha A; Deol A; Saliminia T; Revankar S; Chandrasekar P
    Ann Hematol; 2016 Aug; 95(8):1323-7. PubMed ID: 27225264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.